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Gene therapy treats a disease affecting multiple organ systems
By Stephen Bradt
nervous system,” said Ponder, associate profesinsights into the treatment of individuals
For the first time, researchers have successsor of medicine and assistant professor of bioaffected with these devastating disorders.”
fully used gene therapy to treat a disease that
chemistry and biophysics at Washington UniIn these experiments, two- to three-day-old
affects organs throughout the body of a large
versity. “We’re hopeful that the approach might
dogs with MPS VII received four injections of a
animal.
also be applicable to hemophilia.”
retroviral vector expressing canine β-glucuroniThe study, led by Dr. Mark E. Haskins,
Lysosomal storage diseases such as MPS VII
dase. The vector used was made from the
V’69, of the School and Dr. Katherine Parker
can be treated through enzyme replacement
Moloney murine leukemia virus with a liverPonder of the Washington University School
therapy, but that approach requires regular
specific promoter; at several days of age, canine
of Medicine in St.
liver growth is so
Louis, involved dogs
rapid that transwith a rare disorder
duction occurs
in which an enzyme
readily and β-gludeficiency causes
curonidase is
clouding of the
secreted continucorneas, cardiac disously into the
ease and bone abnorbloodstream.
malities leading to
The enzyme’s
loss of mobility by
activity was subsesix months of age.
quently found at
Newborn dogs treatnormal, stable
ed with hepatic gene
levels for up to 14
therapy maintained
months in the
near-normal mobilitreated dogs; one
ty throughout the
dog has produced
17-month study and
60 times normal
showed little evienzyme for 17
dence of the other
months. Unlike
debilitating signs
other dogs with
normally associated
MPS VII, the treatwith the disease.
ed dogs gained
“While gene ther- Dogs with the genetic disease mucopolysaccharidosis VII and a diagram of the retroviral vector used in intravenous weight normally,
neonatal gene therapy. The untreated 5 month-old dog on the right is unable to stand. The 17 month-old dog on the attaining nearly 90
apy has been used
left, treated at 3 days of age, can stand and run and has not developed most signs of the disease.
previously in dogs,
percent the weight
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this is the first use to
of their unaffected
treat a disorder
littermates, and
affecting multiple organ systems throughout
intravenous injections and is prohibitively
avoided the serious side effects normally associthe body,” said Haskins, professor of pathology
expensive. Bone-marrow transplantation is
ated with lysosomal storage diseases. The βand medical genetics at the School. “Previous
another option but is risky, and compatible
glucuronidase gene does not appear to have
applications of gene therapy in dogs have tardonors are often unavailable.
been inserted into the germ line.
geted disorders affecting a single bodily funcMPS diseases affect 1 in 27,000 live births
Haskins and Ponder were joined in the
tion, such as vision or blood clotting. Like
among humans, but the disease is debilitating
research by Drs. John R. Melniczek, V’92,
many diseases that we might eventually like to
for patients and emotionally wrenching for
Margaret A. Weil, Thomas M. O’Malley,
treat with gene therapy, this one has complex,
their families. Human symptoms include
Patricia A. O’Donnell, Van W. Knox, Hamutal
multisystemic effects.”
growth retardation, mobility problems, facial
Mazrier, N. Matthew Ellinwood, Meg Sleeper,
The experiments involved seven dogs with
deformities, corneal clouding, liver and heart
V’93, Susan W. Volk, V’95, Jean Zweigle and
mucopolysaccharidosis VII, a disorder in
valve abnormalities and mental retardation,
John H. Wolfe, V’82 of Penn’s School of
which the enzyme β-glucuronidase is deficient
among others. Most patients die in childhood.
Veterinary Medicine; Albert M. Maguire of
in activity. Also known as Sly syndrome, MPS
“The gene therapy research of Drs. Haskins,
Penn’s School of Medicine; Lingfei Xu and
VII is among a constellation of lysosomal storPonder and collaborators involving MPS VII
Robert L. Mango of Washington University’s
age diseases; in humans, such disorders
dogs has significant implications for all MPS
School of Medicine; and Gustavo D. Aguirre,
include Tay Sachs disease and Gaucher disease.
disorders,” said Barbara Wedehase, executive
V’68 of Cornell University’s College of
“In theory, the approach should be applicadirector of the National MPS Society, an organVeterinary Medicine. The work was funded by
ble to other lysosomal storage diseases, with
ization of parents of children with MPS. “Their
the National Institutes of Health.
the exception of those that affect the central
current and ongoing research will provide new
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